

# CONTINUING APPLICATION TRANSMITTAL UNDER RULE 1.53(b) IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Customer No. 004372 ARENT FOX KINTNER PLOTKIN & KAHN, PLLC 1050 Connecticut Avenue, N.W.,

Docket No.

108074-00021

Suite 400

Date:

February 1, 2002

Washington, DC 20036-5339 Telephone: (202) 857-6000 Facsimile: (202) 638-4810

Commissioner for Patents Washington, D.C. 20231

Sir:

Transmitted herewith for filing under 37 C.F.R. §1.53(b) is a

☐ Divisional

☐ Continuation-in-Part

application of prior pending Application No. 09/173,565, filed October 16, 1998,

For (Title):

G PROTEIN COUPLED RECEPTOR A4

By (Inventors):

Roman ZASTAWNY

- $\boxtimes$ A Declaration and Power of Attorney is attached. The attached Declaration and Power of Attorney is:
  - a. A copy of the Declaration and Power of Attorney from the parent application. (Used with the same or fewer inventors and (a) a copy of the prior application or (b) a revised, reformatted or edited version of the prior application that does not contain new matter.)
  - b. A new Declaration and Power of Attorney. (Used with the same, fewer or additional inventors and (a) a copy of the prior application, (b) a revised, reformatted or edited version of the prior application that does not contain new matter, or (c) a new specification.)
- The filing fee based on entry of the concurrently filed Preliminary Amendment is calculated  $\boxtimes$ 2. below:

# CLAIMS IN THE APPLICATION AFTER ENTRY OF ANY PRELIMINARY AMENDMENT NOTED BELOW

FOR:	NO. FILED	NO. EXTRA	
BASIC FEE			
TOTAL CLAIMS	61 - 20	= 41	
INDEP CLAIMS	2 - 3	= 0	
☑ MULTIPLE DEPENDENT CLAIMS PRESENTED			

<sup>\*</sup> If the difference is less than zero, enter "0".

SMALL ENTITY			
RATE	FEE	<u>OR</u>	
	\$ 370	<u>OR</u>	
x 9 =	\$369	<u>OR</u>	
x 42=	\$	<u>OR</u>	
+140 =	\$140	<u>OR</u>	
TOTAL	\$879	<u>OR</u>	
•		•	

## OTHER THAN A **SMALL ENTITY**

RATE	FEE	
	\$ 740	
x 18	\$	
x 84	\$	
+280	\$	
TOTAL	\$	

3.	$\boxtimes$	A Check in the amount of \$879.00 to cover the filing fee is attached. The Commissioner
		is hereby authorized to charge any other fees that may be required to complete this filing,
		or to credit any overpayment, to Deposit Account No. 01-2300, referring to client-matter
		number 108074-00021.

4.	Cancel claims	of the application before calculating the filing fee.	At least one
	independent claim is	retained for filing purposes.	

5.	$\boxtimes$	Amend the specification by inserting before the first line the sentence:
♥.	<u> </u>	Andread the appearagners by maditing befole the mating the actification

This is a 🛭 Continu	ation 🔲 Division	Continu	ation-in-Part of	f Application	No. 09/173.56
filed October 16, 1998	, The disclosure	of the pri	or application(s	s) is hereby	incorporated by
reference herein in its e			,	•	•

Rule 1.53(b) Continuing Application of U.S. Application No. 09/173,565 Filed October 16, 1998

6.	$\boxtimes$	Formal drawings (Figs. <u>1-6</u> ) are attached.		
7.		Priority of foreign application No filed in is claimed under 35 U.S.C. §119 and/or §365(b).		
8.		The certified copy was filed in prior Application Noon		
9.		A certified copy of the above foreign application(s) is attached.		
10.		Priority of U.S. Provisional Application(s) No filed is claimed under 35 U.S.C. §119(e).		
11.		Amend the specification by inserting before the first line the sentence:		
		This nonprovisional application claims the benefit of U.S. Provisional Application(s) No filed		
12.	$\boxtimes$	The prior application is assigned of record to <u>Allelix Biopharmaceuticals Inc.</u> recorded at Reel <u>9520</u> , Frame <u>0215</u> on <u>October 16, 1998</u> .		
13.		This application is filed by fewer than all the inventors named in the prior application (37 C.F.R §1.53(b)(1)). Delete the following inventor(s) named in the prior application:		
14.		A Preliminary Amendment is attached.		
15.		An Information Disclosure Statement is attached along with Form PTO-1449 and references.		
16.	$\boxtimes$	Small entity status:		
		a. A small entity statement is attached.		
		b. A small entity statement was filed in the parent application and such status is still proper and desired.		
		C. Small entity status is no longer claimed.		
17.		Other:		
18.		The Power of Attorney in the application is to Robert B. Murray, Reg. No. 22,980; Charles M. Marmelstein, Reg. No. 25,895; George E. Oram, Jr., Reg. No. 27,931; Douglas H. Goldhush, Reg. No. 33,125; Richard J. Berman, Reg. No. 39,107; Murat Ozgu, Reg. No. 44,275; Robert & Carpenter, Reg. No. 34,794; Gregory B. Kang, Reg. No. 45,273; Rustan Hill, Reg. No. 37,351; Hans J. Crosby, Reg. No. 44,634; Brian A. Tollefson, Reg. No. 46,338; David D. Dzara, Reg. No. 47,543, Lynne D. Anderson, Reg. No. 46,412, Michael A. Steinberg, Reg. No. 43,160 and Lynn A. Bristol, Reg. No. 48,898.		

# CUSTOMER NO. 004372 ARENT FOX KINTNER PLOTKIN & KAHN, PLLC 1050 CONNECTICUT AVENUE, N.W., SUITE 400 WASHINGTON, D.C. 20036-5339

Respectfully submitted,

D. Daniel Dzara, K

Registration No. 47,543

ARENT FOX KINTNER PLOTKIN & KAHN, PLLC 1050 Connecticut Avenue, N.W., Suite 400 Washington, D.C. 20036-5339

Tel: (202) 857-6000 Fax: (202) 638-4810

DDD:ksm